Skip to Main Content

Paper Details

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Oncotarget
81
2015
Author NameAffiliation
Claude GardinAvicenne Hospital, University Paris 13
Herv?? DombretSaint-Louis Hospital
Claude PreudhommeLille University Hospital
Claude PreudhommeINSERM
  • 1 - 4

Datasets

Release 1.2